Drug Profile
SBI 101 - Sentien Biotechnologies
Alternative Names: SBI-101Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Sentien Biotechnologies
- Class Stem cell factors
- Mechanism of Action Immunosuppressants; Stem cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute kidney injury; COVID 2019 infections
Most Recent Events
- 19 Nov 2020 Phase-I/II clinical trials in COVID-2019 infections in USA (Parenteral) (NCT04445220)
- 21 Oct 2020 NDR batch#17: No updates; Cross-checked the NCT record and company pipeline. Trial is active, drug is present on the company pipeline; Drug properties and Thes mapping checked
- 26 Jun 2020 Sentien Biotechnologies plans a phase I/II trial for Acute Kidney Injury in COVID-19 subjects. (NCT04445220)